https://scholars.lib.ntu.edu.tw/handle/123456789/637983
標題: | The Psoriasis Therapeutic Potential of a Novel Short Laminin Peptide C16 | 作者: | Ho, Tsung-Chuan Yeh, Shu-I SHOW-LI CHEN Tsao, Yeou-Ping |
關鍵字: | C16 peptide; fibronectin; inflammation; psoriasis; α5β1 integrin | 公開日期: | 27-六月-2019 | 卷: | 20 | 期: | 13 | 來源出版物: | International journal of molecular sciences | 摘要: | Psoriasis is a chronic inflammatory skin disease characterized by excessive growth of keratinocytes and hyperkeratosis in the epidermis. An abnormality of the non-lesional epidermis at an early stage of psoriasis is involved in triggering inflammatory cell infiltration into the dermis. Integrin α5β1 acts as a receptor for fibronectin and has been found to be overexpressed in non-lesional psoriatic epidermis. To investigate whether α5β1 integrin has a potential as a drug target for psoriasis treatment, the α5β1 integrin-binding peptide, C16, was used to obstruct the HaCat keratinocyte cellular responses induced by fibronectin (Fn) in culture and psoriasis-like skin inflammation induced in mice by imiquimod (IMQ). The C16 exhibited antagonistic activity against α5β1 integrin in HaCat cells, with evidence of suppression of the Fn-mediated proliferative, cytoskeletal, and inflammatory responses. Topical treatment with C16 greatly reduced the IMQ-induced epidermal hyperplasia, infiltration of neutrophils/macrophages, and expression of pro-inflammatory mediators in mouse skin. The C16SP (C16-derived short peptide; DITYVRLKF) also exhibited antagonistic activity, suppressing α5β1 integrin activity in culture, and reducing IMQ-induced skin inflammation. Taken together, this study provides the first evidence that α5β1 integrin may be a potential drug target for psoriasis. The synthetic C16 peptide may serve as an agent for psoriasis therapy. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/637983 | ISSN: | 16616596 | DOI: | 10.3390/ijms20133144 |
顯示於: | 微生物學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。